Despite further normalisation in FilmArray, bioMerieux witnessed recovery/ healthy momentum in most other routine areas. Although, as expected, group-wide sales growth moderation was evident. Importantly, profitability came in ahead of (consensus) expectations due to temporarily lower costs. While the worsening COVID-19 situation, especially in the US, may render some near-term support to FilmArray, the rebound in routine businesses is a major promising signal. Our positive stock recommendation ....

02 Sep 2021
Q2: recovering routine business plus some (temporary) profitability tailwinds

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q2: recovering routine business plus some (temporary) profitability tailwinds
- Published:
02 Sep 2021 -
Author:
Anas PATEL -
Pages:
3 -
Despite further normalisation in FilmArray, bioMerieux witnessed recovery/ healthy momentum in most other routine areas. Although, as expected, group-wide sales growth moderation was evident. Importantly, profitability came in ahead of (consensus) expectations due to temporarily lower costs. While the worsening COVID-19 situation, especially in the US, may render some near-term support to FilmArray, the rebound in routine businesses is a major promising signal. Our positive stock recommendation ....